Michael Gold to Treatment Outcome
This is a "connection" page, showing publications Michael Gold has written about Treatment Outcome.
Connection Strength
4.438
-
Association of left ventricular remodeling with cardiac resynchronization therapy outcomes. Heart Rhythm. 2023 02; 20(2):173-180.
Score: 0.089
-
Association of interventricular activation delay with clinical outcomes in cardiac resynchronization therapy. Heart Rhythm. 2023 Mar; 20(3):385-392.
Score: 0.089
-
Infection in patients with subcutaneous implantable cardioverter-defibrillator: Results of the S-ICD Post Approval Study. Heart Rhythm. 2022 Dec; 19(12):1993-2001.
Score: 0.088
-
Role of Electrical Delay in Cardiac Resynchronization Therapy Response. Card Electrophysiol Clin. 2022 06; 14(2):233-241.
Score: 0.086
-
CRT Efficacy in "Mid-Range" QRS Duration Among Asians Contrasted to Non-Asians, and Influence of Height. JACC Clin Electrophysiol. 2022 02; 8(2):211-221.
Score: 0.083
-
The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
Score: 0.083
-
Same-day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database. J Cardiovasc Electrophysiol. 2021 09; 32(9):2432-2440.
Score: 0.082
-
Impact of age on catheter ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2021 04; 32(4):1077-1084.
Score: 0.079
-
Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2021 07; 7(7):871-880.
Score: 0.079
-
Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheter Cardiovasc Interv. 2021 08 01; 98(2):393-400.
Score: 0.079
-
Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
Score: 0.077
-
1-Year Prospective Evaluation of Clinical Outcomes and Shocks: The?Subcutaneous?ICD?Post?Approval Study. JACC Clin Electrophysiol. 2020 11; 6(12):1537-1550.
Score: 0.077
-
The role of electrophysiologic study in high-risk patients with new-onset conduction disturbances following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Electrophysiol. 2020 09; 31(9):2522-2525.
Score: 0.076
-
Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
Score: 0.075
-
Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
Score: 0.074
-
Comparison of measures of ventricular delay on cardiac resynchronization therapy response. Heart Rhythm. 2020 04; 17(4):615-620.
Score: 0.073
-
The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
Score: 0.072
-
Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
Score: 0.066
-
Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
Score: 0.064
-
Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two? Circulation. 2018 01 16; 137(3):217-218.
Score: 0.064
-
The role of interventricular conduction delay to predict clinical response with cardiac resynchronization therapy. Heart Rhythm. 2017 12; 14(12):1748-1755.
Score: 0.063
-
Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017 10; 14(10):1456-1463.
Score: 0.061
-
The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
Score: 0.060
-
The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Fail Clin. 2017 Jan; 13(1):209-223.
Score: 0.059
-
Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017 01; 14(1):e41-e44.
Score: 0.058
-
The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
Score: 0.057
-
Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
Score: 0.056
-
Safety and Efficacy of the Subcutaneous Implantable Defibrillator. J Am Coll Cardiol. 2016 Feb 02; 67(4):445-454.
Score: 0.056
-
The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Card Electrophysiol Clin. 2015 Dec; 7(4):765-79.
Score: 0.055
-
Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
Score: 0.054
-
Clinical experience with subcutaneous implantable cardioverter-defibrillators. Nat Rev Cardiol. 2015 Jul; 12(7):398-405.
Score: 0.053
-
A new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc Electrophysiol. 2015 Apr; 26(4):417-423.
Score: 0.052
-
The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
Score: 0.051
-
Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014 Aug; 11(8):1352-8.
Score: 0.049
-
The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
Score: 0.049
-
Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol. 2013 Sep; 6(5):483-502.
Score: 0.047
-
Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
Score: 0.046
-
The effect of left ventricular electrical delay on AV optimization for cardiac resynchronization therapy. Heart Rhythm. 2013 Jul; 10(7):988-93.
Score: 0.046
-
Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
Score: 0.045
-
Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
Score: 0.044
-
Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
Score: 0.044
-
Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol. 2012 Jan; 23(1):110-8.
Score: 0.042
-
The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
Score: 0.041
-
Safety and efficacy of low-fluence, high-repetition rate versus high-fluence, low-repetition rate 810-nm diode laser for permanent hair removal--a split-face comparison study. J Cosmet Laser Ther. 2011 Aug; 13(4):134-7.
Score: 0.040
-
Cardiac resynchronization therapy for mild heart failure: the time has come. Circulation. 2011 Jan 18; 123(2):195-202.
Score: 0.039
-
The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
Score: 0.039
-
Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
Score: 0.039
-
Cardiac resynchronization therapy in mild heart failure: a review of the REVERSE and MADIT-CRT trials. Curr Cardiol Rep. 2010 Sep; 12(5):367-73.
Score: 0.038
-
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
Score: 0.038
-
Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
Score: 0.035
-
The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
Score: 0.034
-
Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
Score: 0.034
-
Atrial overdrive pacing and incidence of heart failure-related adverse events in permanently paced patients. J Interv Card Electrophysiol. 2007 Jun; 19(1):55-60.
Score: 0.031
-
A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
Score: 0.030
-
Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
Score: 0.025
-
Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
Score: 0.024
-
Effectiveness of rapid atrial pacing for termination of drug refractory atrial fibrillation: results of a dual chamber implantable cardioverter defibrillator trial. Card Electrophysiol Rev. 2003 Dec; 7(4):341-4.
Score: 0.024
-
Distal right ventricular coil position reduces defibrillation thresholds. J Cardiovasc Electrophysiol. 2003 Oct; 14(10):1036-40.
Score: 0.024
-
Treatment of pancreatic pseudoaneurysm with percutaneous transabdominal thrombin injection. J Vasc Surg. 2003 Sep; 38(3):600-2.
Score: 0.024
-
Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials. Circulation. 2023 Mar 07; 147(10):812-823.
Score: 0.023
-
Long-term outcomes in nonprogressors to cardiac resynchronization therapy. Heart Rhythm. 2023 02; 20(2):165-170.
Score: 0.022
-
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
Score: 0.022
-
Epicardial mapping and ablation of ventricular tachycardia from the coronary venous system in post-coronary bypass patients. J Interv Card Electrophysiol. 2023 Jan; 66(1):145-151.
Score: 0.022
-
Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
Score: 0.021
-
Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 2002 Apr; 13(4):332-5.
Score: 0.021
-
The importance of early evaluation after cardiac resynchronization therapy to redefine response: Pooled individual patient analysis from 5 prospective studies. Heart Rhythm. 2022 04; 19(4):595-603.
Score: 0.021
-
Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
Score: 0.021
-
Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
Score: 0.020
-
Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial. Am Heart J. 2021 05; 235:158-162.
Score: 0.020
-
Outcomes of two versus three incision techniques: Results from the subcutaneous ICD post-approval study. J Cardiovasc Electrophysiol. 2021 03; 32(3):792-801.
Score: 0.020
-
Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. Pacing Clin Electrophysiol. 2001 Jan; 24(1):70-4.
Score: 0.020
-
Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1981-5.
Score: 0.019
-
Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
Score: 0.019
-
Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. J Med Econ. 2020 Dec; 23(12):1401-1408.
Score: 0.019
-
Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. J Cardiovasc Electrophysiol. 2020 12; 31(12):3166-3175.
Score: 0.019
-
IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. J Drugs Dermatol. 2020 10 01; 19(10):985-991.
Score: 0.019
-
Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008370.
Score: 0.019
-
Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy. ESC Heart Fail. 2020 10; 7(5):2972-2982.
Score: 0.019
-
Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e008267.
Score: 0.019
-
Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008655.
Score: 0.019
-
ICD therapy in the new millennium. Cardiol Clin. 2000 May; 18(2):375-89.
Score: 0.019
-
Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia. J Comp Eff Res. 2020 04; 9(5):375-385.
Score: 0.019
-
Pacing for patients with congestive heart failure and dilated cardiomyopathy. Cardiol Clin. 2000 Feb; 18(1):55-66.
Score: 0.018
-
Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
Score: 0.018
-
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
Score: 0.018
-
Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm. 2019 12; 16(12):1758-1765.
Score: 0.018
-
Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999 Jan; 137(1):100-3.
Score: 0.017
-
The effect of shock configuration and delivered energy on defibrillation impedance. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):165-8.
Score: 0.017
-
Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
Score: 0.017
-
The effect of delivered energy on defibrillation shock impedance. J Interv Card Electrophysiol. 1998 Sep; 2(3):273-7.
Score: 0.017
-
Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
Score: 0.016
-
The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. Eur J Heart Fail. 2018 04; 20(4):780-791.
Score: 0.016
-
Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. Polaris Investigator Group. Am J Cardiol. 1997 Dec 01; 80(11):1444-7.
Score: 0.016
-
Strength-duration relationship for human transvenous defibrillation. Circulation. 1997 Nov 18; 96(10):3517-20.
Score: 0.016
-
Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
Score: 0.016
-
Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
Score: 0.016
-
Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
Score: 0.016
-
Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. Eur J Heart Fail. 2017 07; 19(7):950-957.
Score: 0.015
-
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J. 2017 May 01; 38(17):1339-1344.
Score: 0.015
-
Predictors of short-term clinical response to cardiac resynchronization therapy. Eur J Heart Fail. 2017 08; 19(8):1056-1063.
Score: 0.015
-
Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
Score: 0.015
-
Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol. 2016 11; 9(11).
Score: 0.015
-
Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With Multipolar Radiofrequency andVaripulseTechnology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks. J Drugs Dermatol. 2016 Nov 01; 15(11):1354-1358.
Score: 0.015
-
Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
Score: 0.015
-
Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
Score: 0.014
-
Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
Score: 0.014
-
Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
Score: 0.014
-
Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
Score: 0.013
-
Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE?Study?and?EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28; 65(16):1605-1615.
Score: 0.013
-
The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. J Card Fail. 2015 Jul; 21(7):601-7.
Score: 0.013
-
Overdrive pacing for atrial flutter. Am J Cardiol. 1994 Nov 15; 74(10):1021-3.
Score: 0.013
-
Clinical epidemiology and predictors of outcome in children hospitalised with influenza A(H1N1)pdm09 in 2009: a prospective national study. Influenza Other Respir Viruses. 2014 Nov; 8(6):636-45.
Score: 0.013
-
HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 Jul 01; 130(1):94-125.
Score: 0.012
-
Long-term effectiveness of the combined minute ventilation and patient activity sensors as predictor of heart failure events in patients treated with cardiac resynchronization therapy: Results of the Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT device Trial (CLEPSYDRA) study. Eur J Heart Fail. 2014 Jun; 16(6):663-70.
Score: 0.012
-
Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
Score: 0.012
-
An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
Score: 0.012
-
A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol. 2013 Jun 01; 12(6):619-25.
Score: 0.012
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
Score: 0.011
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
Score: 0.011
-
Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. Heart Rhythm. 2012 Oct; 9(10):1667-73.
Score: 0.011
-
Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012 Aug 01; 5(4):626-31.
Score: 0.011
-
Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012 Jun; 163(6):954-962.e1.
Score: 0.011
-
Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
Score: 0.011
-
Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
Score: 0.010
-
Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
Score: 0.010
-
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
Score: 0.010
-
Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
Score: 0.010
-
Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
Score: 0.010
-
A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
Score: 0.009
-
Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
Score: 0.009
-
Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
Score: 0.009
-
Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
Score: 0.008
-
Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
Score: 0.007
-
Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol. 2003 Nov; 14(11):1180-6.
Score: 0.006
-
A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20; 42(4):627-33.
Score: 0.006
-
Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
Score: 0.006
-
Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
Score: 0.005
-
Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1741-3.
Score: 0.005
-
Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol. 1997 Nov 01; 80(9):1183-7.
Score: 0.004
-
Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1996 Feb; 97(2):588-95.
Score: 0.003